CA2609376A1 - Construction lipidique pour l'administration d'interferon a un mammifere - Google Patents

Construction lipidique pour l'administration d'interferon a un mammifere Download PDF

Info

Publication number: CA2609376A1
Authority: CA; Canada
Prior art keywords: interferon; lipid; construct; alpha; biotin
Prior art date: 2005-05-23
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002609376A

Other languages

English (en)

Inventor

John R. Lau

W. Blair Geho

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

SDG Technology Inc

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-05-23

Filing date

2006-05-16

Publication date

2006-11-30

2006-03-20 Priority claimed from US11/384,575 external-priority patent/US20070218117A1/en

2006-05-16 Application filed by Individual filed Critical Individual

2006-11-30 Publication of CA2609376A1 publication Critical patent/CA2609376A1/fr

Status Abandoned legal-status Critical Current

Links

150000002632 lipids Chemical class 0.000 title claims abstract description 430
102000014150 Interferons Human genes 0.000 title claims abstract description 275
108010050904 Interferons Proteins 0.000 title claims abstract description 275
229940079322 interferon Drugs 0.000 title claims abstract description 268
238000012384 transportation and delivery Methods 0.000 title claims description 17
241000124008 Mammalia Species 0.000 title claims description 10
239000000203 mixture Substances 0.000 claims abstract description 155
238000000034 method Methods 0.000 claims abstract description 103
210000003494 hepatocyte Anatomy 0.000 claims abstract description 69
102000005962 receptors Human genes 0.000 claims abstract description 62
108020003175 receptors Proteins 0.000 claims abstract description 62
230000027455 binding Effects 0.000 claims abstract description 60
238000011068 loading method Methods 0.000 claims abstract description 41
238000004519 manufacturing process Methods 0.000 claims abstract description 22
241000700605 Viruses Species 0.000 claims abstract description 20
208000005176 Hepatitis C Diseases 0.000 claims abstract description 18
208000006454 hepatitis Diseases 0.000 claims abstract description 10
231100000283 hepatitis Toxicity 0.000 claims abstract description 10
230000015556 catabolic process Effects 0.000 claims abstract description 5
238000006731 degradation reaction Methods 0.000 claims abstract description 5
239000004480 active ingredient Substances 0.000 claims description 120
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 88
-1 interferon-alpha-n3 Proteins 0.000 claims description 78
108010047761 Interferon-alpha Proteins 0.000 claims description 54
102000006992 Interferon-alpha Human genes 0.000 claims description 52
229920002301 cellulose acetate Polymers 0.000 claims description 38
GAMPNQJDUFQVQO-UHFFFAOYSA-N acetic acid;phthalic acid Chemical compound CC(O)=O.OC(=O)C1=CC=CC=C1C(O)=O GAMPNQJDUFQVQO-UHFFFAOYSA-N 0.000 claims description 36
239000011616 biotin Substances 0.000 claims description 35
229960002685 biotin Drugs 0.000 claims description 35
239000003443 antiviral agent Substances 0.000 claims description 34
235000020958 biotin Nutrition 0.000 claims description 32
210000004185 liver Anatomy 0.000 claims description 29
239000000725 suspension Substances 0.000 claims description 29
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 28
239000000243 solution Substances 0.000 claims description 28
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 28
DEQPBRIACBATHE-FXQIFTODSA-N 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]-2-iminopentanoic acid Chemical compound N1C(=O)N[C@@H]2[C@H](CCCC(=N)C(=O)O)SC[C@@H]21 DEQPBRIACBATHE-FXQIFTODSA-N 0.000 claims description 25
BAQMYDQNMFBZNA-MNXVOIDGSA-N biocytin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)NCCCC[C@H](N)C(O)=O)SC[C@@H]21 BAQMYDQNMFBZNA-MNXVOIDGSA-N 0.000 claims description 24
239000011651 chromium Substances 0.000 claims description 24
BAQMYDQNMFBZNA-UHFFFAOYSA-N N-biotinyl-L-lysine Natural products N1C(=O)NC2C(CCCCC(=O)NCCCCC(N)C(O)=O)SCC21 BAQMYDQNMFBZNA-UHFFFAOYSA-N 0.000 claims description 23
VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical group [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 claims description 22
229910052804 chromium Inorganic materials 0.000 claims description 22
239000000463 material Substances 0.000 claims description 19
230000008569 process Effects 0.000 claims description 19
150000001875 compounds Chemical class 0.000 claims description 18
230000007704 transition Effects 0.000 claims description 18
RNPXCFINMKSQPQ-UHFFFAOYSA-N dicetyl hydrogen phosphate Chemical compound CCCCCCCCCCCCCCCCOP(O)(=O)OCCCCCCCCCCCCCCCC RNPXCFINMKSQPQ-UHFFFAOYSA-N 0.000 claims description 15
229940093541 dicetylphosphate Drugs 0.000 claims description 15
235000012000 cholesterol Nutrition 0.000 claims description 14
108010051423 streptavidin-agarose Proteins 0.000 claims description 14
XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Natural products NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 claims description 13
229960004461 interferon beta-1a Drugs 0.000 claims description 13
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 12
108010067216 glycyl-glycyl-glycine Proteins 0.000 claims description 12
LVNGJLRDBYCPGB-LDLOPFEMSA-N (R)-1,2-distearoylphosphatidylethanolamine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[NH3+])OC(=O)CCCCCCCCCCCCCCCCC LVNGJLRDBYCPGB-LDLOPFEMSA-N 0.000 claims description 11
NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 claims description 11
230000003301 hydrolyzing effect Effects 0.000 claims description 11
229940047124 interferons Drugs 0.000 claims description 11
229920000642 polymer Polymers 0.000 claims description 11
159000000000 sodium salts Chemical class 0.000 claims description 11
102100040018 Interferon alpha-2 Human genes 0.000 claims description 10
108010005714 Interferon beta-1b Proteins 0.000 claims description 10
108010079944 Interferon-alpha2b Proteins 0.000 claims description 10
239000012736 aqueous medium Substances 0.000 claims description 10
238000001914 filtration Methods 0.000 claims description 10
150000002430 hydrocarbons Chemical group 0.000 claims description 10
229960003161 interferon beta-1b Drugs 0.000 claims description 10
102000003996 Interferon-beta Human genes 0.000 claims description 9
108090000467 Interferon-beta Proteins 0.000 claims description 9
108010074328 Interferon-gamma Proteins 0.000 claims description 9
102000008070 Interferon-gamma Human genes 0.000 claims description 9
230000000536 complexating effect Effects 0.000 claims description 9
NBZBKCUXIYYUSX-UHFFFAOYSA-N iminodiacetic acid Chemical compound OC(=O)CNCC(O)=O NBZBKCUXIYYUSX-UHFFFAOYSA-N 0.000 claims description 9
229960003130 interferon gamma Drugs 0.000 claims description 9
229960001388 interferon-beta Drugs 0.000 claims description 9
150000001412 amines Chemical class 0.000 claims description 8
GVJXGCIPWAVXJP-UHFFFAOYSA-N 2,5-dioxo-1-oxoniopyrrolidine-3-sulfonate Chemical compound ON1C(=O)CC(S(O)(=O)=O)C1=O GVJXGCIPWAVXJP-UHFFFAOYSA-N 0.000 claims description 7
XWJBVGZSIAZDKJ-FXQIFTODSA-N 2-[3-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]propyl]propanedioic acid Chemical compound N1C(=O)N[C@@H]2[C@H](CCCC(C(=O)O)C(O)=O)SC[C@@H]21 XWJBVGZSIAZDKJ-FXQIFTODSA-N 0.000 claims description 7
208000005331 Hepatitis D Diseases 0.000 claims description 7
206010019771 Hepatitis F Diseases 0.000 claims description 7
206010019773 Hepatitis G Diseases 0.000 claims description 7
239000002253 acid Substances 0.000 claims description 7
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 7
238000005119 centrifugation Methods 0.000 claims description 7
208000005252 hepatitis A Diseases 0.000 claims description 7
208000002672 hepatitis B Diseases 0.000 claims description 7
201000010284 hepatitis E Diseases 0.000 claims description 7
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 7
NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 claims description 6
WDJHALXBUFZDSR-UHFFFAOYSA-N acetoacetic acid Chemical compound CC(=O)CC(O)=O WDJHALXBUFZDSR-UHFFFAOYSA-N 0.000 claims description 6
239000002552 dosage form Substances 0.000 claims description 6
125000001841 imino group Chemical group [H]N=* 0.000 claims description 6
108010042414 interferon gamma-1b Proteins 0.000 claims description 6
229940028862 interferon gamma-1b Drugs 0.000 claims description 6
NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 claims description 5
DNXDWMHPTVQBIP-ZQIUZPCESA-N 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]-n-[6-[(2-iodoacetyl)amino]hexyl]pentanamide Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)NCCCCCCNC(=O)CI)SC[C@@H]21 DNXDWMHPTVQBIP-ZQIUZPCESA-N 0.000 claims description 5
229940095009 interferon gamma-1a Drugs 0.000 claims description 5
239000003456 ion exchange resin Substances 0.000 claims description 5
229920003303 ion-exchange polymer Polymers 0.000 claims description 5
230000002685 pulmonary effect Effects 0.000 claims description 5
150000003335 secondary amines Chemical class 0.000 claims description 5
IVHGFHPEGYPVSM-RLSLOFABSA-N (2,5-dioxopyrrolidin-1-yl) 12-[5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]dodecanoate Chemical compound C([C@H]1[C@H]2NC(=O)N[C@H]2CS1)CCCC(=O)NCCCCCCCCCCCC(=O)ON1C(=O)CCC1=O IVHGFHPEGYPVSM-RLSLOFABSA-N 0.000 claims description 4
BPNHGUOHVHHZMG-WQYNNSOESA-N (3as,4s,6ar)-4-(4-aminobutyl)-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-2-one;hydrochloride Chemical compound Cl.N1C(=O)N[C@@H]2[C@H](CCCCN)SC[C@@H]21 BPNHGUOHVHHZMG-WQYNNSOESA-N 0.000 claims description 4
UXDBPOWEWOXJCE-DIPNUNPCSA-N 1,2-dihexadecyl-sn-glycero-3-phosphoethanolamine Chemical compound CCCCCCCCCCCCCCCCOC[C@H](COP(O)(=O)OCCN)OCCCCCCCCCCCCCCCC UXDBPOWEWOXJCE-DIPNUNPCSA-N 0.000 claims description 4
ALIFRMFPRBTNNH-WFXMLNOXSA-N 12-[5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]dodecanoic acid Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)NCCCCCCCCCCCC(=O)O)SC[C@@H]21 ALIFRMFPRBTNNH-WFXMLNOXSA-N 0.000 claims description 4
HKAVADYDPYUPRD-UHFFFAOYSA-N 1h-pyrazine-2-thione Chemical compound SC1=CN=CC=N1 HKAVADYDPYUPRD-UHFFFAOYSA-N 0.000 claims description 4
KWNGAZCDAJSVLC-OSAWLIQMSA-N 3-(n-maleimidopropionyl)biocytin Chemical compound N([C@@H](CCCCNC(=O)CCCC[C@H]1[C@H]2NC(=O)N[C@H]2CS1)C(=O)O)C(=O)CCN1C(=O)C=CC1=O KWNGAZCDAJSVLC-OSAWLIQMSA-N 0.000 claims description 4
CCSGGWGTGOLEHK-OBJOEFQTSA-N 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]-n-(5-aminopentyl)pentanamide Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)NCCCCCN)SC[C@@H]21 CCSGGWGTGOLEHK-OBJOEFQTSA-N 0.000 claims description 4
IJJWOSAXNHWBPR-HUBLWGQQSA-N 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]-n-(6-hydrazinyl-6-oxohexyl)pentanamide Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)NCCCCCC(=O)NN)SC[C@@H]21 IJJWOSAXNHWBPR-HUBLWGQQSA-N 0.000 claims description 4
XSXHTPJCSHZYFJ-MNXVOIDGSA-N 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]-n-[(5s)-5-amino-6-hydrazinyl-6-oxohexyl]pentanamide Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)NCCCC[C@H](N)C(=O)NN)SC[C@@H]21 XSXHTPJCSHZYFJ-MNXVOIDGSA-N 0.000 claims description 4
NDKQUODALAUTFL-KWBADKCTSA-N 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]-n-[2-[(2-iodoacetyl)amino]ethyl]pentanamide Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)NCCNC(=O)CI)SC[C@@H]21 NDKQUODALAUTFL-KWBADKCTSA-N 0.000 claims description 4
BRLRJZRHRJEWJY-VCOUNFBDSA-N 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]-n-[3-[3-(4-azido-2-nitroanilino)propyl-methylamino]propyl]pentanamide Chemical compound C([C@H]1[C@H]2NC(=O)N[C@H]2CS1)CCCC(=O)NCCCN(C)CCCNC1=CC=C(N=[N+]=[N-])C=C1[N+]([O-])=O BRLRJZRHRJEWJY-VCOUNFBDSA-N 0.000 claims description 4
QLPHBNRMJLFRGO-YDHSSHFGSA-N 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]-n-[6-[3-(pyridin-2-yldisulfanyl)propanoylamino]hexyl]pentanamide Chemical compound C([C@H]1[C@H]2NC(=O)N[C@H]2CS1)CCCC(=O)NCCCCCCNC(=O)CCSSC1=CC=CC=N1 QLPHBNRMJLFRGO-YDHSSHFGSA-N 0.000 claims description 4
CIVGYTYIDWRBQU-UFLZEWODSA-N 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoic acid;pyrrole-2,5-dione Chemical compound O=C1NC(=O)C=C1.N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 CIVGYTYIDWRBQU-UFLZEWODSA-N 0.000 claims description 4
LOIYZIMLLRKKNS-FIKGOQFSSA-N Biotin-xx hydrazide Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)NCCCCCC(=O)NCCCCCC(=O)NN)SC[C@@H]21 LOIYZIMLLRKKNS-FIKGOQFSSA-N 0.000 claims description 4
102000004190 Enzymes Human genes 0.000 claims description 4
108090000790 Enzymes Proteins 0.000 claims description 4
125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 4
238000004587 chromatography analysis Methods 0.000 claims description 4
BHEWJAXNLVWPSC-NRPADANISA-N methyl 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoate Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)OC)SC[C@@H]21 BHEWJAXNLVWPSC-NRPADANISA-N 0.000 claims description 4
229920001223 polyethylene glycol Polymers 0.000 claims description 4
238000007920 subcutaneous administration Methods 0.000 claims description 4
235000000638 D-biotin Nutrition 0.000 claims description 3
239000011665 D-biotin Substances 0.000 claims description 3
DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 claims description 3
125000002618 bicyclic heterocycle group Chemical group 0.000 claims description 3
150000001615 biotins Chemical class 0.000 claims description 2
239000007853 buffer solution Substances 0.000 claims description 2
239000011347 resin Substances 0.000 claims description 2
229920005989 resin Polymers 0.000 claims description 2
229930195734 saturated hydrocarbon Natural products 0.000 claims description 2
229930195735 unsaturated hydrocarbon Natural products 0.000 claims description 2
108010005716 Interferon beta-1a Proteins 0.000 claims 8
YNIUDHSTAXEOHP-UFLZEWODSA-N 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoic acid;ethane-1,2-diamine Chemical compound NCCN.N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YNIUDHSTAXEOHP-UFLZEWODSA-N 0.000 claims 1
238000004064 recycling Methods 0.000 abstract 1
238000009472 formulation Methods 0.000 description 40
239000008194 pharmaceutical composition Substances 0.000 description 33
239000002245 particle Substances 0.000 description 25
239000008139 complexing agent Substances 0.000 description 21
239000004615 ingredient Substances 0.000 description 17
241000699670 Mus sp. Species 0.000 description 16
230000003993 interaction Effects 0.000 description 15
239000002904 solvent Substances 0.000 description 15
241001465754 Metazoa Species 0.000 description 14
235000001014 amino acid Nutrition 0.000 description 14
229940024606 amino acid Drugs 0.000 description 14
239000003795 chemical substances by application Substances 0.000 description 14
239000012071 phase Substances 0.000 description 14
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
239000001257 hydrogen Substances 0.000 description 12
229910052739 hydrogen Inorganic materials 0.000 description 12
150000003904 phospholipids Chemical class 0.000 description 12
210000000952 spleen Anatomy 0.000 description 12
125000002887 hydroxy group Chemical group [H]O* 0.000 description 11
239000000843 powder Substances 0.000 description 11
NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 11
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 10
150000001413 amino acids Chemical class 0.000 description 10
238000004873 anchoring Methods 0.000 description 10
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
125000000524 functional group Chemical group 0.000 description 10
239000003826 tablet Substances 0.000 description 10
241000711549 Hepacivirus C Species 0.000 description 9
125000004057 biotinyl group Chemical group [H]N1C(=O)N([H])[C@]2([H])[C@@]([H])(SC([H])([H])[C@]12[H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(*)=O 0.000 description 9
239000000872 buffer Substances 0.000 description 9
238000006243 chemical reaction Methods 0.000 description 9
239000002270 dispersing agent Substances 0.000 description 9
150000003839 salts Chemical class 0.000 description 9
SJBOEHIKNDEHHO-UHFFFAOYSA-N 2-[2-aminoethyl(carboxymethyl)amino]acetic acid Chemical compound NCCN(CC(O)=O)CC(O)=O SJBOEHIKNDEHHO-UHFFFAOYSA-N 0.000 description 8
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
RPTUSVTUFVMDQK-UHFFFAOYSA-N Hidralazin Chemical compound C1=CC=C2C(NN)=NN=CC2=C1 RPTUSVTUFVMDQK-UHFFFAOYSA-N 0.000 description 8
101710089751 Interferon-induced, double-stranded RNA-activated protein kinase Proteins 0.000 description 8
102100034170 Interferon-induced, double-stranded RNA-activated protein kinase Human genes 0.000 description 8
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 8
150000002148 esters Chemical class 0.000 description 8
125000004435 hydrogen atom Chemical group [H]* 0.000 description 8
230000004576 lipid-binding Effects 0.000 description 8
229910052751 metal Inorganic materials 0.000 description 8
239000002184 metal Substances 0.000 description 8
210000002784 stomach Anatomy 0.000 description 8
239000000126 substance Substances 0.000 description 8
210000001519 tissue Anatomy 0.000 description 8
125000003118 aryl group Chemical group 0.000 description 7
125000004429 atom Chemical group 0.000 description 7
201000010099 disease Diseases 0.000 description 7
239000003814 drug Substances 0.000 description 7
239000000499 gel Substances 0.000 description 7
239000007788 liquid Substances 0.000 description 7
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 7
238000007911 parenteral administration Methods 0.000 description 7
238000002360 preparation method Methods 0.000 description 7
239000003755 preservative agent Substances 0.000 description 7
239000007787 solid Substances 0.000 description 7
239000000375 suspending agent Substances 0.000 description 7
239000003981 vehicle Substances 0.000 description 7
BIABMEZBCHDPBV-BEBVUIBBSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphoglycerol Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCCCCCCCCCC BIABMEZBCHDPBV-BEBVUIBBSA-N 0.000 description 6
208000006154 Chronic hepatitis C Diseases 0.000 description 6
239000004472 Lysine Substances 0.000 description 6
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
239000013543 active substance Substances 0.000 description 6
230000015572 biosynthetic process Effects 0.000 description 6
239000003085 diluting agent Substances 0.000 description 6
239000003937 drug carrier Substances 0.000 description 6
230000000694 effects Effects 0.000 description 6
230000006870 function Effects 0.000 description 6
208000010710 hepatitis C virus infection Diseases 0.000 description 6
125000000623 heterocyclic group Chemical group 0.000 description 6
239000003380 propellant Substances 0.000 description 6
108090000623 proteins and genes Proteins 0.000 description 6
230000004044 response Effects 0.000 description 6
239000003765 sweetening agent Substances 0.000 description 6
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 5
102100040019 Interferon alpha-1/13 Human genes 0.000 description 5
235000019766 L-Lysine Nutrition 0.000 description 5
108010090804 Streptavidin Proteins 0.000 description 5
230000000840 anti-viral effect Effects 0.000 description 5
239000011324 bead Substances 0.000 description 5
238000005859 coupling reaction Methods 0.000 description 5
238000009826 distribution Methods 0.000 description 5
229940079593 drug Drugs 0.000 description 5
239000003995 emulsifying agent Substances 0.000 description 5
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 5
239000000796 flavoring agent Substances 0.000 description 5
235000003599 food sweetener Nutrition 0.000 description 5
230000002440 hepatic effect Effects 0.000 description 5
208000015181 infectious disease Diseases 0.000 description 5
230000004048 modification Effects 0.000 description 5
238000012986 modification Methods 0.000 description 5
239000000047 product Substances 0.000 description 5
235000018102 proteins Nutrition 0.000 description 5
102000004169 proteins and genes Human genes 0.000 description 5
210000000813 small intestine Anatomy 0.000 description 5
125000001424 substituent group Chemical group 0.000 description 5
235000015112 vegetable and seed oil Nutrition 0.000 description 5
239000008158 vegetable oil Substances 0.000 description 5
239000000080 wetting agent Substances 0.000 description 5
108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 4
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
108010010803 Gelatin Proteins 0.000 description 4
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 4
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 4
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 4
230000004913 activation Effects 0.000 description 4
125000000217 alkyl group Chemical group 0.000 description 4
239000011230 binding agent Substances 0.000 description 4
239000008366 buffered solution Substances 0.000 description 4
229910052799 carbon Inorganic materials 0.000 description 4
125000004432 carbon atom Chemical group C* 0.000 description 4
230000008859 change Effects 0.000 description 4
239000003086 colorant Substances 0.000 description 4
239000000470 constituent Substances 0.000 description 4
125000004122 cyclic group Chemical group 0.000 description 4
230000001419 dependent effect Effects 0.000 description 4
235000014113 dietary fatty acids Nutrition 0.000 description 4
UDUSOMRJOPCWHT-UHFFFAOYSA-N disofenin Chemical compound CC(C)C1=CC=CC(C(C)C)=C1NC(=O)CN(CC(O)=O)CC(O)=O UDUSOMRJOPCWHT-UHFFFAOYSA-N 0.000 description 4
239000011363 dried mixture Substances 0.000 description 4
239000000839 emulsion Substances 0.000 description 4
239000000194 fatty acid Substances 0.000 description 4
229930195729 fatty acid Natural products 0.000 description 4
150000004665 fatty acids Chemical class 0.000 description 4
235000013355 food flavoring agent Nutrition 0.000 description 4
239000008273 gelatin Substances 0.000 description 4
229920000159 gelatin Polymers 0.000 description 4
235000019322 gelatine Nutrition 0.000 description 4
235000011852 gelatine desserts Nutrition 0.000 description 4
230000002209 hydrophobic effect Effects 0.000 description 4
239000007924 injection Substances 0.000 description 4
238000002347 injection Methods 0.000 description 4
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 4
229960000310 isoleucine Drugs 0.000 description 4
229940057995 liquid paraffin Drugs 0.000 description 4
239000006194 liquid suspension Substances 0.000 description 4
239000000314 lubricant Substances 0.000 description 4
239000011159 matrix material Substances 0.000 description 4
239000002609 medium Substances 0.000 description 4
239000012528 membrane Substances 0.000 description 4
GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 4
229910052757 nitrogen Inorganic materials 0.000 description 4
239000003960 organic solvent Substances 0.000 description 4
230000036961 partial effect Effects 0.000 description 4
239000000546 pharmaceutical excipient Substances 0.000 description 4
229920001184 polypeptide Polymers 0.000 description 4
230000002335 preservative effect Effects 0.000 description 4
102000004196 processed proteins & peptides Human genes 0.000 description 4
108090000765 processed proteins & peptides Proteins 0.000 description 4
125000006850 spacer group Chemical group 0.000 description 4
238000010254 subcutaneous injection Methods 0.000 description 4
239000007929 subcutaneous injection Substances 0.000 description 4
235000000346 sugar Nutrition 0.000 description 4
239000004094 surface-active agent Substances 0.000 description 4
238000013268 sustained release Methods 0.000 description 4
239000012730 sustained-release form Substances 0.000 description 4
229910052723 transition metal Inorganic materials 0.000 description 4
150000003624 transition metals Chemical class 0.000 description 4
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 3
LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 description 3
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 3
ZKYLXDFZUVDOQI-PEFPKYLJSA-N 2-[5-[(3as,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]ethyl 2,3-diacetyloxypropyl phosphate;triethylazanium Chemical compound CC[NH+](CC)CC.N1C(=O)N[C@@H]2C(CCCCC(=O)NCCOP([O-])(=O)OCC(COC(=O)C)OC(C)=O)SC[C@@H]21 ZKYLXDFZUVDOQI-PEFPKYLJSA-N 0.000 description 3
YUVHRLXBCBTPIP-UHFFFAOYSA-N 3-[2-[[3-hydroxy-5-(hydroxymethyl)-2-methylpyridin-4-yl]methylideneamino]ethyl]-1H-indol-5-ol Chemical compound Cc1ncc(CO)c(C=NCCc2c[nH]c3ccc(O)cc23)c1O YUVHRLXBCBTPIP-UHFFFAOYSA-N 0.000 description 3
PSGGZEHMAFFBAR-UHFFFAOYSA-N 4-[2-(5-butyl-1H-indol-3-yl)ethyliminomethyl]-5-(hydroxymethyl)-2-methylpyridin-3-ol Chemical compound CCCCc1ccc2[nH]cc(CCN=Cc3c(CO)cnc(C)c3O)c2c1 PSGGZEHMAFFBAR-UHFFFAOYSA-N 0.000 description 3
KCSKCIQYNAOBNQ-KBUMHGCDSA-N 5-[(3as,4s,5r,6ar)-2,5-dioxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoic acid Chemical compound N1C(=O)N[C@H]2C[S@@](=O)[C@@H](CCCCC(=O)O)[C@H]21 KCSKCIQYNAOBNQ-KBUMHGCDSA-N 0.000 description 3
SGNZEZHLDUVMMU-GRIHUTHFSA-N 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]-n-(2-aminoethyl)pentanamide;hydrobromide Chemical compound Br.N1C(=O)N[C@@H]2[C@H](CCCCC(=O)NCCN)SC[C@@H]21 SGNZEZHLDUVMMU-GRIHUTHFSA-N 0.000 description 3
235000003911 Arachis Nutrition 0.000 description 3
244000105624 Arachis hypogaea Species 0.000 description 3
239000004215 Carbon black (E152) Substances 0.000 description 3
JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 3
101000959820 Homo sapiens Interferon alpha-1/13 Proteins 0.000 description 3
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 3
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 3
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 3
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
240000007817 Olea europaea Species 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
230000009471 action Effects 0.000 description 3
125000003545 alkoxy group Chemical group 0.000 description 3
125000002947 alkylene group Chemical group 0.000 description 3
239000007864 aqueous solution Substances 0.000 description 3
239000008135 aqueous vehicle Substances 0.000 description 3
239000008280 blood Substances 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
230000037396 body weight Effects 0.000 description 3
238000009835 boiling Methods 0.000 description 3
238000003776 cleavage reaction Methods 0.000 description 3
208000035475 disorder Diseases 0.000 description 3
229940088598 enzyme Drugs 0.000 description 3
235000019441 ethanol Nutrition 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
235000013922 glutamic acid Nutrition 0.000 description 3
239000004220 glutamic acid Substances 0.000 description 3
239000007902 hard capsule Substances 0.000 description 3
229930195733 hydrocarbon Natural products 0.000 description 3
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
108010010648 interferon alfacon-1 Proteins 0.000 description 3
XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 3
235000010445 lecithin Nutrition 0.000 description 3
239000000787 lecithin Substances 0.000 description 3
229940067606 lecithin Drugs 0.000 description 3
150000002736 metal compounds Chemical class 0.000 description 3
239000002480 mineral oil Substances 0.000 description 3
238000010172 mouse model Methods 0.000 description 3
PXHVJJICTQNCMI-UHFFFAOYSA-N nickel Substances [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 3
239000010955 niobium Substances 0.000 description 3
239000004006 olive oil Substances 0.000 description 3
235000008390 olive oil Nutrition 0.000 description 3
229910052760 oxygen Inorganic materials 0.000 description 3
125000004430 oxygen atom Chemical group O* 0.000 description 3
KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
229960001639 penicillamine Drugs 0.000 description 3
125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 3
150000008104 phosphatidylethanolamines Chemical class 0.000 description 3
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 3
230000007017 scission Effects 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
230000008685 targeting Effects 0.000 description 3
238000012360 testing method Methods 0.000 description 3
239000002562 thickening agent Substances 0.000 description 3
230000036962 time dependent Effects 0.000 description 3
230000001052 transient effect Effects 0.000 description 3
PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
LXUKTWZYHRVQQL-HNNXBMFYSA-N (2S)-2-[[3-hydroxy-5-(hydroxymethyl)-2-methylpyridin-4-yl]methylideneamino]-3-phenylpropanoic acid Chemical compound Cc1ncc(CO)c(C=N[C@@H](Cc2ccccc2)C(O)=O)c1O LXUKTWZYHRVQQL-HNNXBMFYSA-N 0.000 description 2
KDIGYCWRAAYWTQ-JTQLQIEISA-N (2S)-2-[[3-hydroxy-5-(hydroxymethyl)-2-methylpyridin-4-yl]methylideneamino]pentanedioic acid Chemical compound C(C=1C(CO)=CN=C(C)C=1O)=N[C@@H](CCC(=O)O)C(=O)O KDIGYCWRAAYWTQ-JTQLQIEISA-N 0.000 description 2
102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
CITHEXJVPOWHKC-UUWRZZSWSA-N 1,2-di-O-myristoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC CITHEXJVPOWHKC-UUWRZZSWSA-N 0.000 description 2
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
WUVABVPUWPFSET-UHFFFAOYSA-N 1h-benzimidazole;2-(carboxymethylamino)propanoic acid Chemical compound C1=CC=C2NC=NC2=C1.OC(=O)C(C)NCC(O)=O WUVABVPUWPFSET-UHFFFAOYSA-N 0.000 description 2
YQIONQPXDLDBDH-UHFFFAOYSA-N 2-[carboxymethyl-[2-[(3-cyano-4-methyl-1h-pyrrol-2-yl)amino]-2-oxoethyl]amino]acetic acid Chemical compound CC1=CNC(NC(=O)CN(CC(O)=O)CC(O)=O)=C1C#N YQIONQPXDLDBDH-UHFFFAOYSA-N 0.000 description 2
IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
LHOSQISBABVKON-UHFFFAOYSA-N 3-oxo-3-phenylpropanethioic s-acid Chemical compound OC(=S)CC(=O)C1=CC=CC=C1 LHOSQISBABVKON-UHFFFAOYSA-N 0.000 description 2
XGKCPVFETQSXJN-UHFFFAOYSA-N 4-benzoyl-3-ethanethioyl-1-hydroxy-2,5-dioxopyrrolidine-3-sulfonic acid Chemical compound O=C1N(O)C(=O)C(C(=S)C)(S(O)(=O)=O)C1C(=O)C1=CC=CC=C1 XGKCPVFETQSXJN-UHFFFAOYSA-N 0.000 description 2
KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 2
244000215068 Acacia senegal Species 0.000 description 2
235000006491 Acacia senegal Nutrition 0.000 description 2
235000019489 Almond oil Nutrition 0.000 description 2
239000004475 Arginine Substances 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
241000416162 Astragalus gummifer Species 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
229910021555 Chromium Chloride Inorganic materials 0.000 description 2
108020004635 Complementary DNA Proteins 0.000 description 2
229920002261 Corn starch Polymers 0.000 description 2
XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 2
108020004414 DNA Proteins 0.000 description 2
102000053602 DNA Human genes 0.000 description 2
QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
239000004471 Glycine Substances 0.000 description 2
229920000084 Gum arabic Polymers 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 2
LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 2
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
235000010643 Leucaena leucocephala Nutrition 0.000 description 2
240000007472 Leucaena leucocephala Species 0.000 description 2
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 2
UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
RJECHNNFRHZQKU-UHFFFAOYSA-N Oelsaeurecholesterylester Natural products C12CCC3(C)C(C(C)CCCC(C)C)CCC3C2CC=C2C1(C)CCC(OC(=O)CCCCCCCC=CCCCCCCCC)C2 RJECHNNFRHZQKU-UHFFFAOYSA-N 0.000 description 2
108091034117 Oligonucleotide Proteins 0.000 description 2
241000288906 Primates Species 0.000 description 2
KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
238000011529 RT qPCR Methods 0.000 description 2
239000002262 Schiff base Substances 0.000 description 2
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
244000000231 Sesamum indicum Species 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
229940100389 Sulfonylurea Drugs 0.000 description 2
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
208000002847 Surgical Wound Diseases 0.000 description 2
YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
239000004473 Threonine Substances 0.000 description 2
229920001615 Tragacanth Polymers 0.000 description 2
QCWXUUIWCKQGHC-UHFFFAOYSA-N Zirconium Chemical compound [Zr] QCWXUUIWCKQGHC-UHFFFAOYSA-N 0.000 description 2
ARIFZLJIERKKEL-SNNHKCHZSA-N [(z)-[(1e)-1-(carbamothioylhydrazinylidene)-3-ethoxybutan-2-ylidene]amino]thiourea Chemical compound CCOC(C)\C(=N/NC(N)=S)\C=N\NC(N)=S ARIFZLJIERKKEL-SNNHKCHZSA-N 0.000 description 2
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
235000010489 acacia gum Nutrition 0.000 description 2
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
229960004150 aciclovir Drugs 0.000 description 2
238000005903 acid hydrolysis reaction Methods 0.000 description 2
230000002378 acidificating effect Effects 0.000 description 2
235000004279 alanine Nutrition 0.000 description 2
239000008168 almond oil Substances 0.000 description 2
150000001408 amides Chemical class 0.000 description 2
239000008346 aqueous phase Substances 0.000 description 2
239000003125 aqueous solvent Substances 0.000 description 2
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
235000009582 asparagine Nutrition 0.000 description 2
229960001230 asparagine Drugs 0.000 description 2
235000003704 aspartic acid Nutrition 0.000 description 2
238000003556 assay Methods 0.000 description 2
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 2
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
125000002619 bicyclic group Chemical group 0.000 description 2
238000009395 breeding Methods 0.000 description 2
230000001488 breeding effect Effects 0.000 description 2
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
239000006172 buffering agent Substances 0.000 description 2
229910000019 calcium carbonate Inorganic materials 0.000 description 2
239000001506 calcium phosphate Substances 0.000 description 2
229910000389 calcium phosphate Inorganic materials 0.000 description 2
235000011010 calcium phosphates Nutrition 0.000 description 2
210000004027 cell Anatomy 0.000 description 2
235000010980 cellulose Nutrition 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
238000001311 chemical methods and process Methods 0.000 description 2
RJECHNNFRHZQKU-RMUVNZEASA-N cholesteryl oleate Chemical compound C([C@@H]12)C[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@H]3[C@@H]1CC=C1[C@]2(C)CC[C@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)C1 RJECHNNFRHZQKU-RMUVNZEASA-N 0.000 description 2
239000012501 chromatography medium Substances 0.000 description 2
QSWDMMVNRMROPK-UHFFFAOYSA-K chromium(3+) trichloride Chemical compound [Cl-].[Cl-].[Cl-].[Cr+3] QSWDMMVNRMROPK-UHFFFAOYSA-K 0.000 description 2
239000011248 coating agent Substances 0.000 description 2
238000000576 coating method Methods 0.000 description 2
239000003240 coconut oil Substances 0.000 description 2
235000019864 coconut oil Nutrition 0.000 description 2
239000007859 condensation product Substances 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
239000010949 copper Substances 0.000 description 2
229960003067 cystine Drugs 0.000 description 2
238000013461 design Methods 0.000 description 2
150000004985 diamines Chemical class 0.000 description 2
VILAVOFMIJHSJA-UHFFFAOYSA-N dicarbon monoxide Chemical group [C]=C=O VILAVOFMIJHSJA-UHFFFAOYSA-N 0.000 description 2
230000001079 digestive effect Effects 0.000 description 2
IZFHEQBZOYJLPK-UHFFFAOYSA-N dihydrolipoic acid Chemical compound OC(=O)CCCCC(S)CCS IZFHEQBZOYJLPK-UHFFFAOYSA-N 0.000 description 2
ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 2
239000003974 emollient agent Substances 0.000 description 2
238000006047 enzymatic hydrolysis reaction Methods 0.000 description 2
YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
239000000945 filler Substances 0.000 description 2
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
235000004554 glutamine Nutrition 0.000 description 2
239000010931 gold Substances 0.000 description 2
229910052736 halogen Inorganic materials 0.000 description 2
150000002367 halogens Chemical class 0.000 description 2
125000005842 heteroatom Chemical group 0.000 description 2
BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
150000004687 hexahydrates Chemical class 0.000 description 2
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
229960002474 hydralazine Drugs 0.000 description 2
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
125000002140 imidazol-4-yl group Chemical group [H]N1C([H])=NC([*])=C1[H] 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
239000003701 inert diluent Substances 0.000 description 2
238000001802 infusion Methods 0.000 description 2
239000007972 injectable composition Substances 0.000 description 2
229960003358 interferon alfacon-1 Drugs 0.000 description 2
238000010255 intramuscular injection Methods 0.000 description 2
239000007927 intramuscular injection Substances 0.000 description 2
238000004255 ion exchange chromatography Methods 0.000 description 2
125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 2
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
239000003446 ligand Substances 0.000 description 2
239000006193 liquid solution Substances 0.000 description 2
239000007937 lozenge Substances 0.000 description 2
235000018977 lysine Nutrition 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
239000011572 manganese Substances 0.000 description 2
239000003550 marker Substances 0.000 description 2
229960001428 mercaptopurine Drugs 0.000 description 2
229930182817 methionine Natural products 0.000 description 2
125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 2
238000002156 mixing Methods 0.000 description 2
239000002808 molecular sieve Substances 0.000 description 2
239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 2
238000000465 moulding Methods 0.000 description 2
231100000252 nontoxic Toxicity 0.000 description 2
230000003000 nontoxic effect Effects 0.000 description 2
230000000269 nucleophilic effect Effects 0.000 description 2
239000003921 oil Substances 0.000 description 2
235000019198 oils Nutrition 0.000 description 2
230000003647 oxidation Effects 0.000 description 2
238000007254 oxidation reaction Methods 0.000 description 2
239000001301 oxygen Substances 0.000 description 2
239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
KJFMBFZCATUALV-UHFFFAOYSA-N phenolphthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2C(=O)O1 KJFMBFZCATUALV-UHFFFAOYSA-N 0.000 description 2
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
125000002525 phosphocholine group Chemical group OP(=O)(OCC[N+](C)(C)C)O* 0.000 description 2
125000005498 phthalate group Chemical group 0.000 description 2
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
229920000053 polysorbate 80 Polymers 0.000 description 2
239000001267 polyvinylpyrrolidone Substances 0.000 description 2
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
230000002441 reversible effect Effects 0.000 description 2
239000010948 rhodium Substances 0.000 description 2
239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 2
239000008159 sesame oil Substances 0.000 description 2
235000011803 sesame oil Nutrition 0.000 description 2
URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
239000001488 sodium phosphate Substances 0.000 description 2
229910000162 sodium phosphate Inorganic materials 0.000 description 2
RMLUKZWYIKEASN-UHFFFAOYSA-M sodium;2-amino-9-(2-hydroxyethoxymethyl)purin-6-olate Chemical compound [Na+].O=C1[N-]C(N)=NC2=C1N=CN2COCCO RMLUKZWYIKEASN-UHFFFAOYSA-M 0.000 description 2
239000007901 soft capsule Substances 0.000 description 2
238000005063 solubilization Methods 0.000 description 2
230000007928 solubilization Effects 0.000 description 2
235000010356 sorbitol Nutrition 0.000 description 2
239000000600 sorbitol Substances 0.000 description 2
239000003381 stabilizer Substances 0.000 description 2
238000006467 substitution reaction Methods 0.000 description 2
125000000446 sulfanediyl group Chemical group *S* 0.000 description 2
YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical compound OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 2
230000002459 sustained effect Effects 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
229940034208 thyroxine Drugs 0.000 description 2
XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 2
239000010936 titanium Substances 0.000 description 2
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
229940005605 valeric acid Drugs 0.000 description 2
239000011701 zinc Substances 0.000 description 2
229910052726 zirconium Inorganic materials 0.000 description 2
FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
QGVQZRDQPDLHHV-DPAQBDIFSA-N (3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthrene-3-thiol Chemical compound C1C=C2C[C@@H](S)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 QGVQZRDQPDLHHV-DPAQBDIFSA-N 0.000 description 1
LXTQKGIUEYHCTI-UHFFFAOYSA-N (5-bromo-2-hydroxyphenyl) acetate Chemical compound CC(=O)OC1=CC(Br)=CC=C1O LXTQKGIUEYHCTI-UHFFFAOYSA-N 0.000 description 1
125000006273 (C1-C3) alkyl group Chemical group 0.000 description 1
DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
AGNGYMCLFWQVGX-AGFFZDDWSA-N (e)-1-[(2s)-2-amino-2-carboxyethoxy]-2-diazonioethenolate Chemical compound OC(=O)[C@@H](N)CO\C([O-])=C\[N+]#N AGNGYMCLFWQVGX-AGFFZDDWSA-N 0.000 description 1
UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 1
ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 description 1
YFWHNAWEOZTIPI-DIPNUNPCSA-N 1,2-dioctadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCCCC YFWHNAWEOZTIPI-DIPNUNPCSA-N 0.000 description 1
UNEATYXSUBPPKP-UHFFFAOYSA-N 1,3-Diisopropylbenzene Chemical class CC(C)C1=CC=CC(C(C)C)=C1 UNEATYXSUBPPKP-UHFFFAOYSA-N 0.000 description 1
IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
IJMWTMDPDGSOIZ-UHFFFAOYSA-N 2-(carboxymethylamino)acetic acid;1h-pyrrol-2-amine Chemical compound NC1=CC=CN1.OC(=O)CNCC(O)=O IJMWTMDPDGSOIZ-UHFFFAOYSA-N 0.000 description 1
LUAPJUACEIGURZ-SPXVIFFHSA-N 2-[[(2R)-2,3-di(octadecanoyloxy)propoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium phosphate Chemical compound P(=O)([O-])([O-])[O-].C(CCCCCCCCCCCCCCCCC)(=O)OC[C@@H](OC(CCCCCCCCCCCCCCCCC)=O)COP(=O)(O)OCC[N+](C)(C)C.C(CCCCCCCCCCCCCCCCC)(=O)OC[C@@H](OC(CCCCCCCCCCCCCCCCC)=O)COP(=O)(O)OCC[N+](C)(C)C.C(CCCCCCCCCCCCCCCCC)(=O)OC[C@@H](OC(CCCCCCCCCCCCCCCCC)=O)COP(=O)(O)OCC[N+](C)(C)C LUAPJUACEIGURZ-SPXVIFFHSA-N 0.000 description 1
GCBNPHYPETXYJJ-UHFFFAOYSA-N 2-[[2-(2-butylanilino)-2-oxoethyl]-(carboxymethyl)amino]acetic acid Chemical compound CCCCC1=CC=CC=C1NC(=O)CN(CC(O)=O)CC(O)=O GCBNPHYPETXYJJ-UHFFFAOYSA-N 0.000 description 1
XNORVCNKXNZYSE-UHFFFAOYSA-N 2-[[2-(3-butoxyanilino)-2-oxoethyl]-(carboxymethyl)amino]acetic acid Chemical compound CCCCOC1=CC=CC(NC(=O)CN(CC(O)=O)CC(O)=O)=C1 XNORVCNKXNZYSE-UHFFFAOYSA-N 0.000 description 1
PAYYOEIKGWDQKN-UHFFFAOYSA-N 2-[[2-(3-butylanilino)-2-oxoethyl]-(carboxymethyl)amino]acetic acid Chemical compound CCCCC1=CC=CC(NC(=O)CN(CC(O)=O)CC(O)=O)=C1 PAYYOEIKGWDQKN-UHFFFAOYSA-N 0.000 description 1
XSYSSUAGVNOMCE-UHFFFAOYSA-N 2-[[2-(4-butylanilino)-2-oxoethyl]-(carboxymethyl)amino]acetic acid Chemical compound CCCCC1=CC=C(NC(=O)CN(CC(O)=O)CC(O)=O)C=C1 XSYSSUAGVNOMCE-UHFFFAOYSA-N 0.000 description 1
OVRQCZURNANBSK-UHFFFAOYSA-N 2-[[2-(4-tert-butylanilino)-2-oxoethyl]-(carboxymethyl)amino]acetic acid Chemical compound CC(C)(C)C1=CC=C(NC(=O)CN(CC(O)=O)CC(O)=O)C=C1 OVRQCZURNANBSK-UHFFFAOYSA-N 0.000 description 1
VTKBOFPXOFGXMQ-UHFFFAOYSA-N 2-[[2-[(5-benzyl-3-cyano-4-methyl-1h-pyrrol-2-yl)amino]-2-oxoethyl]-(carboxymethyl)amino]acetic acid Chemical compound N1C(NC(=O)CN(CC(O)=O)CC(O)=O)=C(C#N)C(C)=C1CC1=CC=CC=C1 VTKBOFPXOFGXMQ-UHFFFAOYSA-N 0.000 description 1
AIYRRERVRZFPKN-UHFFFAOYSA-N 2-[carboxymethyl-[2-(2,3-dimethylanilino)-2-oxoethyl]amino]acetic acid Chemical compound CC1=CC=CC(NC(=O)CN(CC(O)=O)CC(O)=O)=C1C AIYRRERVRZFPKN-UHFFFAOYSA-N 0.000 description 1
RISSLKJAGXQNAQ-UHFFFAOYSA-N 2-[carboxymethyl-[2-(2,4-dimethylanilino)-2-oxoethyl]amino]acetic acid Chemical compound CC1=CC=C(NC(=O)CN(CC(O)=O)CC(O)=O)C(C)=C1 RISSLKJAGXQNAQ-UHFFFAOYSA-N 0.000 description 1
XQPIALCZXISDPU-UHFFFAOYSA-N 2-[carboxymethyl-[2-(2,5-dimethylanilino)-2-oxoethyl]amino]acetic acid Chemical compound CC1=CC=C(C)C(NC(=O)CN(CC(O)=O)CC(O)=O)=C1 XQPIALCZXISDPU-UHFFFAOYSA-N 0.000 description 1
WNIDXAKKFOKNEF-UHFFFAOYSA-N 2-[carboxymethyl-[2-(2,6-diethylanilino)-2-oxoethyl]amino]acetic acid Chemical compound CCC1=CC=CC(CC)=C1NC(=O)CN(CC(O)=O)CC(O)=O WNIDXAKKFOKNEF-UHFFFAOYSA-N 0.000 description 1
OVMLLDXAYBWFBC-UHFFFAOYSA-N 2-[carboxymethyl-[2-(2-hexoxyanilino)-2-oxoethyl]amino]acetic acid Chemical compound CCCCCCOC1=CC=CC=C1NC(=O)CN(CC(O)=O)CC(O)=O OVMLLDXAYBWFBC-UHFFFAOYSA-N 0.000 description 1
ZZWVTHKCDSHEAU-UHFFFAOYSA-N 2-[carboxymethyl-[2-(3,4-dimethylanilino)-2-oxoethyl]amino]acetic acid Chemical compound CC1=CC=C(NC(=O)CN(CC(O)=O)CC(O)=O)C=C1C ZZWVTHKCDSHEAU-UHFFFAOYSA-N 0.000 description 1
WYLNABZHAULYNV-UHFFFAOYSA-N 2-[carboxymethyl-[2-(3,5-dimethylanilino)-2-oxoethyl]amino]acetic acid Chemical compound CC1=CC(C)=CC(NC(=O)CN(CC(O)=O)CC(O)=O)=C1 WYLNABZHAULYNV-UHFFFAOYSA-N 0.000 description 1
IYPHTGWJAAENCL-UHFFFAOYSA-N 2-[carboxymethyl-[2-(4-hexoxyanilino)-2-oxoethyl]amino]acetic acid Chemical compound CCCCCCOC1=CC=C(NC(=O)CN(CC(O)=O)CC(O)=O)C=C1 IYPHTGWJAAENCL-UHFFFAOYSA-N 0.000 description 1
BVXRFBZNNRXJGR-UHFFFAOYSA-N 2-[carboxymethyl-[2-[(3-cyano-4,5-dimethyl-1h-pyrrol-2-yl)amino]-2-oxoethyl]amino]acetic acid Chemical compound CC=1NC(NC(=O)CN(CC(O)=O)CC(O)=O)=C(C#N)C=1C BVXRFBZNNRXJGR-UHFFFAOYSA-N 0.000 description 1
CFWRDBDJAOHXSH-UHFFFAOYSA-N 2-azaniumylethyl 2,3-diacetyloxypropyl phosphate Chemical compound CC(=O)OCC(OC(C)=O)COP(O)(=O)OCCN CFWRDBDJAOHXSH-UHFFFAOYSA-N 0.000 description 1
BMUXBWLKTHLRQC-UHFFFAOYSA-N 2-azanylethanoic acid Chemical compound NCC(O)=O.NCC(O)=O.NCC(O)=O BMUXBWLKTHLRQC-UHFFFAOYSA-N 0.000 description 1
WWVANQJRLPIHNS-BKPPORCPSA-N 2-iminobiotin Chemical compound N1C(=N)N[C@H]2[C@H](CCCCC(=O)O)SC[C@H]21 WWVANQJRLPIHNS-BKPPORCPSA-N 0.000 description 1
KTOQRRDVVIDEAA-UHFFFAOYSA-N 2-methylpropane Chemical compound [CH2]C(C)C KTOQRRDVVIDEAA-UHFFFAOYSA-N 0.000 description 1
XFQYOFLFNKCHLG-UHFFFAOYSA-N 3-acetyl-6-bromochromen-2-one Chemical compound BrC1=CC=C2OC(=O)C(C(=O)C)=CC2=C1 XFQYOFLFNKCHLG-UHFFFAOYSA-N 0.000 description 1
JVQIKJMSUIMUDI-UHFFFAOYSA-N 3-pyrroline Chemical compound C1NCC=C1 JVQIKJMSUIMUDI-UHFFFAOYSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
229920000936 Agarose Polymers 0.000 description 1
102100027211 Albumin Human genes 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
239000005995 Aluminium silicate Substances 0.000 description 1
102000004400 Aminopeptidases Human genes 0.000 description 1
108090000915 Aminopeptidases Proteins 0.000 description 1
208000035049 Blood-Borne Infections Diseases 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
229910014033 C-OH Inorganic materials 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
208000017667 Chronic Disease Diseases 0.000 description 1
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
XZMCDFZZKTWFGF-UHFFFAOYSA-N Cyanamide Chemical class NC#N XZMCDFZZKTWFGF-UHFFFAOYSA-N 0.000 description 1
OABOXRPGTFRBFZ-IMJSIDKUSA-N Cys-Cys Chemical compound SC[C@H](N)C(=O)N[C@@H](CS)C(O)=O OABOXRPGTFRBFZ-IMJSIDKUSA-N 0.000 description 1
229910014570 C—OH Inorganic materials 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
239000003155 DNA primer Substances 0.000 description 1
BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
241000283086 Equidae Species 0.000 description 1
VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
239000005977 Ethylene Substances 0.000 description 1
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
102000008857 Ferritin Human genes 0.000 description 1
108050000784 Ferritin Proteins 0.000 description 1
238000008416 Ferritin Methods 0.000 description 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
GYHNNYVSQQEPJS-UHFFFAOYSA-N Gallium Chemical compound [Ga] GYHNNYVSQQEPJS-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
244000068988 Glycine max Species 0.000 description 1
235000010469 Glycine max Nutrition 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
102000001554 Hemoglobins Human genes 0.000 description 1
108010054147 Hemoglobins Proteins 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
LCWXJXMHJVIJFK-UHFFFAOYSA-N Hydroxylysine Natural products NCC(O)CC(N)CC(O)=O LCWXJXMHJVIJFK-UHFFFAOYSA-N 0.000 description 1
108060003951 Immunoglobulin Proteins 0.000 description 1
108010078049 Interferon alpha-2 Proteins 0.000 description 1
FPTRWYHXARAFPO-UHFFFAOYSA-N Iprofenin Chemical compound CC(C)C1=CC=C(NC(=O)CN(CC(O)=O)CC(O)=O)C=C1 FPTRWYHXARAFPO-UHFFFAOYSA-N 0.000 description 1
AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
150000008545 L-lysines Chemical class 0.000 description 1
125000001176 L-lysyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C([H])([H])C([H])([H])C(N([H])[H])([H])[H] 0.000 description 1
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
235000019759 Maize starch Nutrition 0.000 description 1
PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
238000006683 Mannich reaction Methods 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
102000007474 Multiprotein Complexes Human genes 0.000 description 1
108010085220 Multiprotein Complexes Proteins 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
101000926534 Mus musculus Interferon-induced, double-stranded RNA-activated protein kinase Proteins 0.000 description 1
SULVSHBBSDLJAM-UHFFFAOYSA-N N=C1C=C2C=CC=CC2=C(C(C(O)=O)C(O)=O)C1C(=O)C1C(=N)C=C2C=CC=CC2=C1C(C(O)=O)C(=O)O Chemical compound N=C1C=C2C=CC=CC2=C(C(C(O)=O)C(O)=O)C1C(=O)C1C(=N)C=C2C=CC=CC2=C1C(C(O)=O)C(=O)O SULVSHBBSDLJAM-UHFFFAOYSA-N 0.000 description 1
RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
241001494479 Pecora Species 0.000 description 1
102000057297 Pepsin A Human genes 0.000 description 1
108090000284 Pepsin A Proteins 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
102000007327 Protamines Human genes 0.000 description 1
108010007568 Protamines Proteins 0.000 description 1
102000001253 Protein Kinase Human genes 0.000 description 1
WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
241000700159 Rattus Species 0.000 description 1
IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
239000004141 Sodium laurylsulphate Substances 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
241000282887 Suidae Species 0.000 description 1
239000004098 Tetracycline Substances 0.000 description 1
FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
102000004142 Trypsin Human genes 0.000 description 1
108090000631 Trypsin Proteins 0.000 description 1
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
108020000999 Viral RNA Proteins 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
WERKSKAQRVDLDW-ANOHMWSOSA-N [(2s,3r,4r,5r)-2,3,4,5,6-pentahydroxyhexyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO WERKSKAQRVDLDW-ANOHMWSOSA-N 0.000 description 1
JLZVTZOKUJLPGY-UHFFFAOYSA-K [O-]C(CC(CC([O-])=O)(C([O-])=O)O)=O.N.[Zr+4] Chemical compound [O-]C(CC(CC([O-])=O)(C([O-])=O)O)=O.N.[Zr+4] JLZVTZOKUJLPGY-UHFFFAOYSA-K 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
229910052768 actinide Inorganic materials 0.000 description 1
150000001255 actinides Chemical class 0.000 description 1
125000002252 acyl group Chemical group 0.000 description 1
FFINMCNLQNTKLU-UHFFFAOYSA-N adipiodone Chemical compound OC(=O)C1=C(I)C=C(I)C(NC(=O)CCCCC(=O)NC=2C(=C(C(O)=O)C(I)=CC=2I)I)=C1I FFINMCNLQNTKLU-UHFFFAOYSA-N 0.000 description 1
230000002411 adverse Effects 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
230000001476 alcoholic effect Effects 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
230000004075 alteration Effects 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
235000012211 aluminium silicate Nutrition 0.000 description 1
150000003862 amino acid derivatives Chemical group 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
239000003945 anionic surfactant Substances 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000003466 anti-cipated effect Effects 0.000 description 1
230000001028 anti-proliverative effect Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
239000003429 antifungal agent Substances 0.000 description 1
229940121375 antifungal agent Drugs 0.000 description 1
229910052787 antimony Inorganic materials 0.000 description 1
WATWJIUSRGPENY-UHFFFAOYSA-N antimony atom Chemical compound [Sb] WATWJIUSRGPENY-UHFFFAOYSA-N 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
238000013459 approach Methods 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
108010084541 asialoorosomucoid Proteins 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
238000000889 atomisation Methods 0.000 description 1
229950011321 azaserine Drugs 0.000 description 1
235000013871 bee wax Nutrition 0.000 description 1
239000012166 beeswax Substances 0.000 description 1
230000008901 benefit Effects 0.000 description 1
PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 1
GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 description 1
239000003833 bile salt Substances 0.000 description 1
229940093761 bile salts Drugs 0.000 description 1
229920002988 biodegradable polymer Polymers 0.000 description 1
239000004621 biodegradable polymer Substances 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
239000004305 biphenyl Substances 0.000 description 1
235000010290 biphenyl Nutrition 0.000 description 1
229910052797 bismuth Inorganic materials 0.000 description 1
JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
230000036765 blood level Effects 0.000 description 1
229910052794 bromium Inorganic materials 0.000 description 1
UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
GHAFORRTMVIXHS-UHFFFAOYSA-L bromosulfophthalein sodium Chemical compound [Na+].[Na+].C1=C(S([O-])(=O)=O)C(O)=CC=C1C1(C=2C=C(C(O)=CC=2)S([O-])(=O)=O)C(C(Br)=C(Br)C(Br)=C2Br)=C2C(=O)O1 GHAFORRTMVIXHS-UHFFFAOYSA-L 0.000 description 1
235000019437 butane-1,3-diol Nutrition 0.000 description 1
125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
210000004899 c-terminal region Anatomy 0.000 description 1
229910052793 cadmium Inorganic materials 0.000 description 1
BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 1
235000010216 calcium carbonate Nutrition 0.000 description 1
FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
239000002775 capsule Substances 0.000 description 1
150000001718 carbodiimides Chemical class 0.000 description 1
150000001721 carbon Chemical group 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
229960000541 cetyl alcohol Drugs 0.000 description 1
239000000460 chlorine Substances 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
YHHSONZFOIEMCP-UHFFFAOYSA-M choline phosphate(1-) Chemical compound C[N+](C)(C)CCOP([O-])([O-])=O YHHSONZFOIEMCP-UHFFFAOYSA-M 0.000 description 1
LJAOOBNHPFKCDR-UHFFFAOYSA-K chromium(3+) trichloride hexahydrate Chemical compound O.O.O.O.O.O.[Cl-].[Cl-].[Cl-].[Cr+3] LJAOOBNHPFKCDR-UHFFFAOYSA-K 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
229960002173 citrulline Drugs 0.000 description 1
235000013477 citrulline Nutrition 0.000 description 1
229910017052 cobalt Inorganic materials 0.000 description 1
239000010941 cobalt Substances 0.000 description 1
GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
238000004440 column chromatography Methods 0.000 description 1
235000021310 complex sugar Nutrition 0.000 description 1
239000007891 compressed tablet Substances 0.000 description 1
IQFVPQOLBLOTPF-HKXUKFGYSA-L congo red Chemical compound [Na+].[Na+].C1=CC=CC2=C(N)C(/N=N/C3=CC=C(C=C3)C3=CC=C(C=C3)/N=N/C3=C(C4=CC=CC=C4C(=C3)S([O-])(=O)=O)N)=CC(S([O-])(=O)=O)=C21 IQFVPQOLBLOTPF-HKXUKFGYSA-L 0.000 description 1
230000021615 conjugation Effects 0.000 description 1
239000002872 contrast media Substances 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
150000004696 coordination complex Chemical class 0.000 description 1
229910052802 copper Inorganic materials 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
230000008878 coupling Effects 0.000 description 1
239000007822 coupling agent Substances 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical group BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
108010004073 cysteinylcysteine Proteins 0.000 description 1
230000007423 decrease Effects 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 1
238000010586 diagram Methods 0.000 description 1
235000019700 dicalcium phosphate Nutrition 0.000 description 1
238000009792 diffusion process Methods 0.000 description 1
210000002249 digestive system Anatomy 0.000 description 1
125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
HDFXRQJQZBPDLF-UHFFFAOYSA-L disodium hydrogen carbonate Chemical compound [Na+].[Na+].OC([O-])=O.OC([O-])=O HDFXRQJQZBPDLF-UHFFFAOYSA-L 0.000 description 1
NFRFUGBXJTXTMZ-QYKZUBHNSA-L disodium;[(2r)-2,3-di(hexadecanoyloxy)propyl] phosphate Chemical compound [Na+].[Na+].CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])([O-])=O)OC(=O)CCCCCCCCCCCCCCC NFRFUGBXJTXTMZ-QYKZUBHNSA-L 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
239000006196 drop Substances 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
230000012202 endocytosis Effects 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
230000007071 enzymatic hydrolysis Effects 0.000 description 1
YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 1
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
ZJXZSIYSNXKHEA-UHFFFAOYSA-N ethyl dihydrogen phosphate Chemical compound CCOP(O)(O)=O ZJXZSIYSNXKHEA-UHFFFAOYSA-N 0.000 description 1
238000013265 extended release Methods 0.000 description 1
239000003889 eye drop Substances 0.000 description 1
229940012356 eye drops Drugs 0.000 description 1
239000003925 fat Substances 0.000 description 1
235000019197 fats Nutrition 0.000 description 1
238000005243 fluidization Methods 0.000 description 1
229910052731 fluorine Inorganic materials 0.000 description 1
239000011737 fluorine Substances 0.000 description 1
125000002541 furyl group Chemical group 0.000 description 1
229910052733 gallium Inorganic materials 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
238000001641 gel filtration chromatography Methods 0.000 description 1
238000005227 gel permeation chromatography Methods 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
229910052732 germanium Inorganic materials 0.000 description 1
GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 description 1
239000008103 glucose Substances 0.000 description 1
229940074045 glyceryl distearate Drugs 0.000 description 1
229940075507 glyceryl monostearate Drugs 0.000 description 1
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
229910052737 gold Inorganic materials 0.000 description 1
125000005843 halogen group Chemical group 0.000 description 1
210000003128 head Anatomy 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
FBPFZTCFMRRESA-UHFFFAOYSA-N hexane-1,2,3,4,5,6-hexol Chemical compound OCC(O)C(O)C(O)C(O)CO FBPFZTCFMRRESA-UHFFFAOYSA-N 0.000 description 1
125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000001183 hydrocarbyl group Chemical group 0.000 description 1
QJHBJHUKURJDLG-UHFFFAOYSA-N hydroxy-L-lysine Natural products NCCCCC(NO)C(O)=O QJHBJHUKURJDLG-UHFFFAOYSA-N 0.000 description 1
125000002349 hydroxyamino group Chemical group [H]ON([H])[*] 0.000 description 1
230000002519 immonomodulatory effect Effects 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
102000018358 immunoglobulin Human genes 0.000 description 1
229940072221 immunoglobulins Drugs 0.000 description 1
238000002513 implantation Methods 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
229910052738 indium Inorganic materials 0.000 description 1
APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 description 1
MOFVSTNWEDAEEK-UHFFFAOYSA-M indocyanine green Chemical compound [Na+].[O-]S(=O)(=O)CCCCN1C2=CC=C3C=CC=CC3=C2C(C)(C)C1=CC=CC=CC=CC1=[N+](CCCCS([O-])(=O)=O)C2=CC=C(C=CC=C3)C3=C2C1(C)C MOFVSTNWEDAEEK-UHFFFAOYSA-M 0.000 description 1
229960004657 indocyanine green Drugs 0.000 description 1
230000006698 induction Effects 0.000 description 1
229940090438 infergen Drugs 0.000 description 1
229950000038 interferon alfa Drugs 0.000 description 1
229960003521 interferon alfa-2a Drugs 0.000 description 1
230000031891 intestinal absorption Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
229940029355 iodipamide Drugs 0.000 description 1
FZDZULUFHNDEDJ-UHFFFAOYSA-N ioglycamic acid Chemical compound OC(=O)C1=C(I)C=C(I)C(NC(=O)COCC(=O)NC=2C(=C(C(O)=O)C(I)=CC=2I)I)=C1I FZDZULUFHNDEDJ-UHFFFAOYSA-N 0.000 description 1
229960004876 ioglycamic acid Drugs 0.000 description 1
238000005342 ion exchange Methods 0.000 description 1
229910052741 iridium Inorganic materials 0.000 description 1
GKOZUEZYRPOHIO-UHFFFAOYSA-N iridium atom Chemical compound [Ir] GKOZUEZYRPOHIO-UHFFFAOYSA-N 0.000 description 1
229910052742 iron Inorganic materials 0.000 description 1
RTOYJIFECJCKIK-UHFFFAOYSA-K iron(3+) phosphate tetrahydrate Chemical compound O.O.O.O.[Fe+3].[O-]P([O-])([O-])=O RTOYJIFECJCKIK-UHFFFAOYSA-K 0.000 description 1
NJWYTAHMQKIIQQ-UHFFFAOYSA-N iron(3+);hydrate Chemical compound O.[Fe+3] NJWYTAHMQKIIQQ-UHFFFAOYSA-N 0.000 description 1
YHGPYBQVSJBGHH-UHFFFAOYSA-H iron(3+);trisulfate;pentahydrate Chemical compound O.O.O.O.O.[Fe+3].[Fe+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O YHGPYBQVSJBGHH-UHFFFAOYSA-H 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
239000008101 lactose Substances 0.000 description 1
229910052746 lanthanum Inorganic materials 0.000 description 1
FZLIPJUXYLNCLC-UHFFFAOYSA-N lanthanum atom Chemical compound [La] FZLIPJUXYLNCLC-UHFFFAOYSA-N 0.000 description 1
239000012669 liquid formulation Substances 0.000 description 1
208000019423 liver disease Diseases 0.000 description 1
230000002934 lysing effect Effects 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
229910052748 manganese Inorganic materials 0.000 description 1
230000000873 masking effect Effects 0.000 description 1
238000005259 measurement Methods 0.000 description 1
MHPZZZZLAQGTHT-UHFFFAOYSA-N mebrofenin Chemical compound CC1=CC(C)=C(NC(=O)CN(CC(O)=O)CC(O)=O)C(C)=C1Br MHPZZZZLAQGTHT-UHFFFAOYSA-N 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
102000006240 membrane receptors Human genes 0.000 description 1
108020004084 membrane receptors Proteins 0.000 description 1
QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
229910052753 mercury Inorganic materials 0.000 description 1
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
239000007932 molded tablet Substances 0.000 description 1
229910052750 molybdenum Inorganic materials 0.000 description 1
239000011733 molybdenum Substances 0.000 description 1
CWQXQMHSOZUFJS-UHFFFAOYSA-N molybdenum disulfide Chemical compound S=[Mo]=S CWQXQMHSOZUFJS-UHFFFAOYSA-N 0.000 description 1
ZSSVQAGPXAAOPV-UHFFFAOYSA-K molybdenum trichloride Chemical compound Cl[Mo](Cl)Cl ZSSVQAGPXAAOPV-UHFFFAOYSA-K 0.000 description 1
125000000896 monocarboxylic acid group Chemical group 0.000 description 1
210000000214 mouth Anatomy 0.000 description 1
FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
125000003506 n-propoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
125000001624 naphthyl group Chemical group 0.000 description 1
238000002663 nebulization Methods 0.000 description 1
125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
229910052759 nickel Inorganic materials 0.000 description 1
229910052758 niobium Inorganic materials 0.000 description 1
GUCVJGMIXFAOAE-UHFFFAOYSA-N niobium atom Chemical compound [Nb] GUCVJGMIXFAOAE-UHFFFAOYSA-N 0.000 description 1
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
239000012299 nitrogen atmosphere Substances 0.000 description 1
125000004433 nitrogen atom Chemical group N* 0.000 description 1
239000000346 nonvolatile oil Substances 0.000 description 1
238000005935 nucleophilic addition reaction Methods 0.000 description 1
239000002777 nucleoside Substances 0.000 description 1
150000003833 nucleoside derivatives Chemical class 0.000 description 1
239000007764 o/w emulsion Substances 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
229960003104 ornithine Drugs 0.000 description 1
229910052762 osmium Inorganic materials 0.000 description 1
SYQBFIAQOQZEGI-UHFFFAOYSA-N osmium atom Chemical compound [Os] SYQBFIAQOQZEGI-UHFFFAOYSA-N 0.000 description 1
238000004806 packaging method and process Methods 0.000 description 1
229910052763 palladium Inorganic materials 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
238000003921 particle size analysis Methods 0.000 description 1
239000013618 particulate matter Substances 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
229940002988 pegasys Drugs 0.000 description 1
108010092853 peginterferon alfa-2a Proteins 0.000 description 1
108010092851 peginterferon alfa-2b Proteins 0.000 description 1
229940106366 pegintron Drugs 0.000 description 1
125000004115 pentoxy group Chemical group [*]OC([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
229910052697 platinum Inorganic materials 0.000 description 1
229910052699 polonium Inorganic materials 0.000 description 1
HZEBHPIOVYHPMT-UHFFFAOYSA-N polonium atom Chemical compound [Po] HZEBHPIOVYHPMT-UHFFFAOYSA-N 0.000 description 1
238000003752 polymerase chain reaction Methods 0.000 description 1
239000011148 porous material Substances 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
239000013615 primer Substances 0.000 description 1
125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical class CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
229940048914 protamine Drugs 0.000 description 1
125000006239 protecting group Chemical group 0.000 description 1
108060006633 protein kinase Proteins 0.000 description 1
125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
KOUKXHPPRFNWPP-UHFFFAOYSA-N pyrazine-2,5-dicarboxylic acid;hydrate Chemical compound O.OC(=O)C1=CN=C(C(O)=O)C=N1 KOUKXHPPRFNWPP-UHFFFAOYSA-N 0.000 description 1
238000003753 real-time PCR Methods 0.000 description 1
239000013557 residual solvent Substances 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
229910052702 rhenium Inorganic materials 0.000 description 1
WUAPFZMCVAUBPE-UHFFFAOYSA-N rhenium atom Chemical compound [Re] WUAPFZMCVAUBPE-UHFFFAOYSA-N 0.000 description 1
229910052703 rhodium Inorganic materials 0.000 description 1
MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 description 1
229960000329 ribavirin Drugs 0.000 description 1
HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
229920002477 rna polymer Polymers 0.000 description 1
229930187593 rose bengal Natural products 0.000 description 1
AZJPTIGZZTZIDR-UHFFFAOYSA-L rose bengal Chemical compound [K+].[K+].[O-]C(=O)C1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1C1=C2C=C(I)C(=O)C(I)=C2OC2=C(I)C([O-])=C(I)C=C21 AZJPTIGZZTZIDR-UHFFFAOYSA-L 0.000 description 1
229940081623 rose bengal Drugs 0.000 description 1
STRXNPAVPKGJQR-UHFFFAOYSA-N rose bengal A Natural products O1C(=O)C(C(=CC=C2Cl)Cl)=C2C21C1=CC(I)=C(O)C(I)=C1OC1=C(I)C(O)=C(I)C=C21 STRXNPAVPKGJQR-UHFFFAOYSA-N 0.000 description 1
229910052707 ruthenium Inorganic materials 0.000 description 1
CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
229940081974 saccharin Drugs 0.000 description 1
235000019204 saccharin Nutrition 0.000 description 1
239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
229940085605 saccharin sodium Drugs 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
229910052706 scandium Inorganic materials 0.000 description 1
SIXSYDAISGFNSX-UHFFFAOYSA-N scandium atom Chemical compound [Sc] SIXSYDAISGFNSX-UHFFFAOYSA-N 0.000 description 1
238000000926 separation method Methods 0.000 description 1
238000007493 shaping process Methods 0.000 description 1
238000004904 shortening Methods 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
229910052709 silver Inorganic materials 0.000 description 1
239000004332 silver Substances 0.000 description 1
239000007974 sodium acetate buffer Substances 0.000 description 1
BHZOKUMUHVTPBX-UHFFFAOYSA-M sodium acetic acid acetate Chemical compound [Na+].CC(O)=O.CC([O-])=O BHZOKUMUHVTPBX-UHFFFAOYSA-M 0.000 description 1
235000010413 sodium alginate Nutrition 0.000 description 1
239000000661 sodium alginate Substances 0.000 description 1
229940005550 sodium alginate Drugs 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
235000011008 sodium phosphates Nutrition 0.000 description 1
229940080313 sodium starch Drugs 0.000 description 1
239000008247 solid mixture Substances 0.000 description 1
238000000638 solvent extraction Methods 0.000 description 1
239000004334 sorbic acid Substances 0.000 description 1
235000010199 sorbic acid Nutrition 0.000 description 1
229940075582 sorbic acid Drugs 0.000 description 1
235000011069 sorbitan monooleate Nutrition 0.000 description 1
239000001593 sorbitan monooleate Substances 0.000 description 1
229940035049 sorbitan monooleate Drugs 0.000 description 1
241000894007 species Species 0.000 description 1
230000009870 specific binding Effects 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
230000000707 stereoselective effect Effects 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
239000000758 substrate Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
RVEZZJVBDQCTEF-UHFFFAOYSA-N sulfenic acid Chemical compound SO RVEZZJVBDQCTEF-UHFFFAOYSA-N 0.000 description 1
229960001734 sulfobromophthalein Drugs 0.000 description 1
150000003457 sulfones Chemical class 0.000 description 1
150000003458 sulfonic acid derivatives Chemical class 0.000 description 1
125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
150000003462 sulfoxides Chemical class 0.000 description 1
229910052717 sulfur Inorganic materials 0.000 description 1
239000011593 sulfur Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
230000001839 systemic circulation Effects 0.000 description 1
238000012385 systemic delivery Methods 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
229910052715 tantalum Inorganic materials 0.000 description 1
GUVRBAGPIYLISA-UHFFFAOYSA-N tantalum atom Chemical compound [Ta] GUVRBAGPIYLISA-UHFFFAOYSA-N 0.000 description 1
229910052713 technetium Inorganic materials 0.000 description 1
GKLVYJBZJHMRIY-UHFFFAOYSA-N technetium atom Chemical compound [Tc] GKLVYJBZJHMRIY-UHFFFAOYSA-N 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
229960002180 tetracycline Drugs 0.000 description 1
229930101283 tetracycline Natural products 0.000 description 1
235000019364 tetracycline Nutrition 0.000 description 1
150000003522 tetracyclines Chemical class 0.000 description 1
GORLMDNEWNWWBP-UHFFFAOYSA-J tetrafluorozirconium;hydrate Chemical compound O.F[Zr](F)(F)F GORLMDNEWNWWBP-UHFFFAOYSA-J 0.000 description 1
VXYRNRFVDXPZKA-UHFFFAOYSA-N tetrahydrate;hydrofluoride Chemical compound O.O.O.O.F VXYRNRFVDXPZKA-UHFFFAOYSA-N 0.000 description 1
UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
229910052716 thallium Inorganic materials 0.000 description 1
BKVIYDNLLOSFOA-UHFFFAOYSA-N thallium Chemical compound [Tl] BKVIYDNLLOSFOA-UHFFFAOYSA-N 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
150000003568 thioethers Chemical class 0.000 description 1
229930192474 thiophene Natural products 0.000 description 1
229910052719 titanium Inorganic materials 0.000 description 1
229950003937 tolonium Drugs 0.000 description 1
HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 description 1
JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 1
230000032258 transport Effects 0.000 description 1
XIOAYKRRSJTLOZ-UHFFFAOYSA-K tribromochromium;hexahydrate Chemical compound O.O.O.O.O.O.[Cr+3].[Br-].[Br-].[Br-] XIOAYKRRSJTLOZ-UHFFFAOYSA-K 0.000 description 1
YPFBRNLUIFQCQL-UHFFFAOYSA-K tribromomolybdenum Chemical compound Br[Mo](Br)Br YPFBRNLUIFQCQL-UHFFFAOYSA-K 0.000 description 1
239000012588 trypsin Substances 0.000 description 1
WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 1
229910052721 tungsten Inorganic materials 0.000 description 1
239000010937 tungsten Substances 0.000 description 1
239000004474 valine Substances 0.000 description 1
229910052720 vanadium Inorganic materials 0.000 description 1
GPPXJZIENCGNKB-UHFFFAOYSA-N vanadium Chemical compound [V]#[V] GPPXJZIENCGNKB-UHFFFAOYSA-N 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
239000000341 volatile oil Substances 0.000 description 1
239000007762 w/o emulsion Substances 0.000 description 1
229910052727 yttrium Inorganic materials 0.000 description 1
VWQVUPCCIRVNHF-UHFFFAOYSA-N yttrium atom Chemical compound [Y] VWQVUPCCIRVNHF-UHFFFAOYSA-N 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1
DUNKXUFBGCUVQW-UHFFFAOYSA-J zirconium tetrachloride Chemical compound Cl[Zr](Cl)(Cl)Cl DUNKXUFBGCUVQW-UHFFFAOYSA-J 0.000 description 1
XLMQAUWIRARSJG-UHFFFAOYSA-J zirconium(iv) iodide Chemical compound [Zr+4].[I-].[I-].[I-].[I-] XLMQAUWIRARSJG-UHFFFAOYSA-J 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/217—IFN-gamma
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
- A61K47/544—Phospholipids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Virology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Dispersion Chemistry (AREA)
Biotechnology (AREA)
Biophysics (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)

CA002609376A 2005-05-23 2006-05-16 Construction lipidique pour l'administration d'interferon a un mammifere Abandoned CA2609376A1 (fr)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US68387805P	2005-05-23	2005-05-23
US60/683,878		2005-05-23
US11/384,575 US20070218117A1 (en)	2006-03-20	2006-03-20	Supra molecular construct for delivery of interferon to a mammal
US11/384,575		2006-03-20
PCT/US2006/019118 WO2006127360A2 (fr)	2005-05-23	2006-05-16	Construction lipidique pour l'administration d'interferon a un mammifere

Publications (1)

Publication Number	Publication Date
CA2609376A1 true CA2609376A1 (fr)	2006-11-30

Family

ID=37452604

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002609376A Abandoned CA2609376A1 (fr)	2005-05-23	2006-05-16	Construction lipidique pour l'administration d'interferon a un mammifere

Country Status (6)

Country	Link
EP (1)	EP1883395A4 (fr)
JP (1)	JP2008542270A (fr)
KR (1)	KR20080042045A (fr)
AU (1)	AU2006249479A1 (fr)
CA (1)	CA2609376A1 (fr)
WO (1)	WO2006127360A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2009018609A1 (fr) *	2007-08-03	2009-02-12	Biotrom Limited	Compositions et procédés antivirus de l'hépatite c
US8962015B2 (en) *	2007-09-28	2015-02-24	Sdg, Inc.	Orally bioavailable lipid-based constructs
BRPI0820791A2 (pt) *	2007-12-17	2015-06-16	Lux Innovate Ltd	Composições e métodos para manutenção de sistemas de condução e contenção de fluido
US20150265679A1 (en)	2012-11-02	2015-09-24	The United States Of America, As Represented By Secretary, Department Of Health And Human Services	Method of reducing adverse effects in a cancer patient undregoing treatment with a mek inhibitor
CN111690539A (zh) *	2020-07-07	2020-09-22	安徽农业大学	高效秸秆纤维素分解菌的筛选及应用
CN116940384A (zh) *	2020-11-27	2023-10-24	D&D制药技术股份有限公司	具有与生物素部分、脂肪酸部分或其组合偶联的生物活性材料缀合物的口服制剂
EP4252780A1 (fr) *	2020-11-27	2023-10-04	D&D Pharmatech Inc.	Conjugué de matériau biologiquement actif ayant une fraction biotine, un fraction d'acide gras, ou une combinaison de celles-ci couplées à celui-ci

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4603044A (en) *	1983-01-06	1986-07-29	Technology Unlimited, Inc.	Hepatocyte Directed Vesicle delivery system
GB9426484D0 (en) *	1994-12-08	1995-03-08	Ciba Geigy Ag	Compositions
TW520297B (en) *	1996-10-11	2003-02-11	Sequus Pharm Inc	Fusogenic liposome composition and method

2006
- 2006-05-16 AU AU2006249479A patent/AU2006249479A1/en not_active Abandoned
- 2006-05-16 WO PCT/US2006/019118 patent/WO2006127360A2/fr not_active Ceased
- 2006-05-16 JP JP2008513540A patent/JP2008542270A/ja not_active Withdrawn
- 2006-05-16 KR KR1020077029917A patent/KR20080042045A/ko not_active Withdrawn
- 2006-05-16 EP EP06770516A patent/EP1883395A4/fr not_active Withdrawn
- 2006-05-16 CA CA002609376A patent/CA2609376A1/fr not_active Abandoned

Also Published As

Publication number	Publication date
WO2006127360A2 (fr)	2006-11-30
WO2006127360A3 (fr)	2008-01-10
EP1883395A4 (fr)	2012-07-04
AU2006249479A1 (en)	2006-11-30
EP1883395A2 (fr)	2008-02-06
KR20080042045A (ko)	2008-05-14
JP2008542270A (ja)	2008-11-27

Publication	Publication Date	Title
DK2859015T3 (en)	2018-06-18	LIGANDS MODIFIED BY CIRCULAR MODIFICATION AS AGONISTS AND ANTAGONISTS
US8257735B2 (en)	2012-09-04	Method of increasing the bioavailability of recombinant human insulin isophane in a patient
EP2205217B1 (fr)	2017-12-13	Structures à base lipidique et à biodisponibilité orale
US10463616B2 (en)	2019-11-05	Lipid construct for delivery of insulin to a mammal
CA2515892A1 (fr)	2004-09-02	Vehicule d'administration de medicament lipophile et methodes d'utilisation correspondantes
EP3391876B1 (fr)	2021-03-10	Construction lipidique pour administration d'insuline à un mammifère
CA2609376A1 (fr)	2006-11-30	Construction lipidique pour l'administration d'interferon a un mammifere
CN103649106B (zh)	2016-01-20	用于治疗神经退行性和缺血性脑疾病的化合物和药学组合
US7871641B2 (en)	2011-01-18	Hepatocyte-targeting vehicle for delivery of glargine insulin to a mammal
US20070218117A1 (en)	2007-09-20	Supra molecular construct for delivery of interferon to a mammal
US20100129428A1 (en)	2010-05-27	Supra molecular construct for delivery of interferon to a mammal
JP2023533797A (ja)	2023-08-04	脂質複合体を含む経口医薬組成物
US20220110870A1 (en)	2022-04-14	Lipid construct for delivery of insulin to a mammal
AU2012247063B2 (en)	2015-07-30	Lipid construct for delivery of insulin to a mammal
CA2864366C (fr)	2016-04-05	Construction de lipide comportant un lipide amphipathique, du cholesterol, du dicetyl phosphate et un recepteur hepatocyte liant une molecule
DK1883394T3 (en)	2018-06-25	Lipid construct for delivering insulin to a mammal
AU2015249189A1 (en)	2015-11-26	Lipid construct for delivery of insulin to a mammal
HK1116396A (en)	2008-12-24	Lipid construct for delivery of insulin to a mammal
HK1116396B (en)	2019-07-05	Lipid construct for delivery of insulin to a mammal
HK1262603A1 (en)	2020-01-17	Lipid construct for delivery of insulin to a mammal
HK1262603B (en)	2021-11-26	Lipid construct for delivery of insulin to a mammal
JPH01238537A (ja)	1989-09-22	肝障害治療剤
HK1259503A1 (en)	2019-11-29	Orally bioavailable lipid-based constructs

Legal Events

Date	Code	Title	Description
2012-05-16	FZDE	Discontinued